Glaukos Corporation (GKOS) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Medical - Devices
EV/EBITDA
N/A
—
5yr avg: 1514.34
P/FCF
N/A
—
5yr avg: N/A
30Y Low45.9·High45.9
P/B Ratio
↑
11.63
↑+62% vs avg
5yr avg: 7.18
30Y Low3.3·High11.4
ROE
↓
-26.4%
↑-28% vs avg
5yr avg: -20.6%
30Y Low-39%·High4%
Debt/EBITDA
N/A
—
5yr avg: 247.50
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
GKOS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Glaukos Corporation currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7.8B | $6.5B | $7.9B | $3.8B | $2.1B | $2.1B | $3.3B | $2.2B | $2.0B | $882M | $1.3B |
| Enterprise Value | $7.9B | $6.5B | $7.8B | $4.1B | $2.3B | $2.3B | $3.5B | $2.3B | $2.0B | $857M | $1.2B |
| P/E Ratio → | -40.68 | — | — | — | — | — | — | 147.22 | — | — | 285.83 |
| P/S Ratio | 15.39 | 12.73 | 20.63 | 12.23 | 7.33 | 7.02 | 14.89 | 9.46 | 10.94 | 5.54 | 10.93 |
| P/B Ratio | 11.63 | 9.84 | 10.31 | 8.34 | 3.91 | 3.51 | 5.02 | 3.33 | 11.41 | 6.38 | 10.66 |
| P/FCF | — | — | — | — | — | — | — | — | 232.05 | 45.94 | 207.35 |
| P/OCF | — | — | — | — | — | 83.50 | — | — | 105.16 | 34.57 | 101.60 |
P/E links to full P/E history page with 30-year chart
GKOS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 12.82 | 20.46 | 13.16 | 8.26 | 7.98 | 15.67 | 9.50 | 10.78 | 5.38 | 10.87 |
| EV / EBITDA | — | — | — | — | — | 1514.34 | — | — | — | 267.84 | 138.80 |
| EV / EBIT | — | — | — | — | — | — | — | — | — | 857364.65 | 293.34 |
| EV / FCF | — | — | — | — | — | — | — | — | 228.56 | 44.66 | 206.28 |
GKOS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Glaukos Corporation earns an operating margin of -17.1%. Operating margins have expanded from -40.9% to -17.1% over the past 3 years, signaling improving operational efficiency. A negative ROE of -26.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.5% | 77.5% | 75.5% | 76.0% | 75.6% | 77.3% | 59.2% | 83.7% | 86.2% | 86.8% | 85.9% |
| Operating Margin | -17.1% | -17.1% | -31.9% | -40.9% | -29.1% | -11.2% | -54.9% | -21.2% | -7.2% | -1.4% | 3.7% |
| Net Profit Margin | -37.0% | -37.0% | -38.2% | -42.8% | -35.1% | -16.9% | -53.5% | 6.5% | -7.1% | -0.1% | 4.0% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -26.4% | -26.4% | -23.8% | -27.2% | -17.8% | -7.9% | -18.0% | 3.6% | -8.3% | -0.1% | 4.3% |
| ROA | -20.1% | -20.1% | -15.3% | -13.4% | -9.0% | -4.6% | -13.2% | 3.0% | -6.9% | -0.1% | 3.6% |
| ROIC | -9.2% | -9.2% | -12.6% | -12.5% | -7.4% | -2.9% | -12.1% | -9.1% | -7.6% | -1.5% | 3.3% |
| ROCE | -10.3% | -10.3% | -13.9% | -13.8% | -8.0% | -3.3% | -14.4% | -10.7% | -8.2% | -1.8% | 4.0% |
GKOS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $49M ($140M total debt minus $91M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.21 | 0.21 | 0.14 | 0.83 | 0.72 | 0.65 | 0.41 | 0.11 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | 247.50 | — | — | — | — | — |
| Net Debt / Equity | — | 0.07 | -0.08 | 0.63 | 0.50 | 0.48 | 0.26 | 0.02 | -0.17 | -0.18 | -0.06 |
| Net Debt / EBITDA | — | — | — | — | — | 182.49 | — | — | — | -7.66 | -0.72 |
| Debt / FCF | — | — | — | — | — | — | — | — | -3.49 | -1.28 | -1.08 |
| Interest Coverage | -18.71 | -18.71 | -13.50 | -8.81 | -6.17 | -2.68 | -8.37 | -18.51 | — | — | 6.98 |
GKOS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Glaukos Corporation's current ratio of 4.69x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 4.06x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 5.34x to 4.69x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.69 | 4.69 | 5.99 | 5.34 | 6.13 | 7.67 | 9.45 | 4.56 | 5.81 | 5.58 | 7.09 |
| Quick Ratio | 4.06 | 4.06 | 5.22 | 4.78 | 5.61 | 7.31 | 9.13 | 3.82 | 5.38 | 5.16 | 6.68 |
| Cash Ratio | 2.75 | 2.75 | 4.25 | 3.99 | 4.87 | 6.53 | 8.14 | 3.02 | 4.63 | 4.44 | 5.65 |
| Asset Turnover | — | 0.57 | 0.39 | 0.33 | 0.26 | 0.26 | 0.22 | 0.29 | 0.88 | 0.96 | 0.85 |
| Inventory Turnover | 1.80 | 1.80 | 1.63 | 1.80 | 1.82 | 2.90 | 5.80 | 0.91 | 1.89 | 1.88 | 2.36 |
| Days Sales Outstanding | — | 78.12 | 57.82 | 46.22 | 46.55 | 41.51 | 58.51 | 59.17 | 37.60 | 38.17 | 45.64 |
GKOS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Glaukos Corporation does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | 0.7% | — | — | 0.3% |
| FCF Yield | — | — | — | — | — | — | — | — | 0.4% | 2.2% | 0.5% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $57M | $53M | $48M | $47M | $46M | $44M | $41M | $35M | $34M | $36M |
Peer Comparison
Compare GKOS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 GKOSYou | $8B | -40.7 | — | — | 77.5% | -17.1% | -26.4% | -9.2% | — |
 ATRC | $1B | -122.7 | 82.6 | 30.9 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
 NVCR | $2B | -13.0 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 TNDM | $1B | -6.4 | — | — | 52.3% | -7.7% | -97.9% | -10.0% | — |
 INSP | $1B | 9.9 | 20.3 | 17.7 | 85.4% | 5.6% | 19.8% | 6.0% | 0.5 |
 EW | $48B | 45.3 | 25.4 | 35.8 | 78.1% | 27.0% | 10.5% | 15.5% | 0.4 |
 ALGN | $12B | 29.9 | 14.0 | 24.6 | 68.3% | 15.3% | 10.4% | 15.4% | 0.1 |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 IRTC | $4B | -85.0 | — | 112.4 | 70.6% | -4.9% | -36.6% | -5.2% | — |
 RXST | $299M | -7.6 | — | — | 76.6% | -35.8% | -14.0% | -13.3% | — |
 LNTH | $6B | 25.2 | 13.7 | 15.8 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
| Healthcare Median | — | 22.2 | 14.0 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
See GKOS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GKOS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GKOS vs ATRC
Side-by-side business, growth, and profitability comparison vs AtriCure, Inc..
Start ComparisonGKOS — Frequently Asked Questions
Quick answers to the most common questions about buying GKOS stock.
What is Glaukos Corporation's P/E ratio?
Glaukos Corporation's current P/E ratio is -40.7x. The historical average is 147.2x.
What is Glaukos Corporation's ROE?
Glaukos Corporation's return on equity (ROE) is -26.4%. The historical average is -14.6%.
Is GKOS stock overvalued?
Based on historical data, Glaukos Corporation is trading at a P/E of -40.7x. Compare with industry peers and growth rates for a complete picture.
What are Glaukos Corporation's profit margins?
Glaukos Corporation has 77.5% gross margin and -17.1% operating margin.